Three molecules are currently in development and SPECMET platform:

  1. MD1003 in primary and secondary progressive multiple sclerosis (MS) and in X-linked adrenoleukodystrophy
  2. MD1103 in autism spectrum disorders
  3. MD1105 in Alzheimer’s disease
  4. SPECMET platform

 

MedDay SA au capital de 116 660 €
Siège social : 96 Boulevard Haussmann 75008 Paris
RCS PARIS 534 957 865
Publication Director : Dr Frédéric Sedel